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been performed. Using an AML mouse model driven by expression of AML1/ETO9a we demonstrated that treatment of mice bearing t(8;21) AML with the HDACi panobinostat caused a robust anti-leukemic response, that did not require functional p53 nor activation of conventional apoptotic pathways. Panobinostat triggered terminal myeloid differentiation via proteasomal degradation of AML1/ETO9a. Importantly, conditional AML1/ETO9a deletion phenocopied the effects of panobinostat and other HDACi, indicating that destabilization of AML1/ETO9a is critical for the anti-leukemic activity of these agents.
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INTRODUCTION
Modulation of chromatin through histone modification is essential in regulating fundamental biological processes such as gene transcription and DNA repair 1 . The biological consequences are determined by the combinatorial pattern of the histone modifications, which is regulated by specific enzymes that are classified into 'writers', 'erasers' and 'readers'. Writers, such as histone acetyltransferases (HATs) or histone methyltransferases (HMTs) add distinct chemical modifications to histones, while erasers, including histone deacetylases (HDACs) and histone demethylases, remove these modifications. Lastly, epigenetic readers specifically recognize modified histones and recruit various effector molecules involved in transcriptional and chromatin regulation 2 . Lysine acetylation -one of the major regulatory histone modifications -is controlled by the opposing activities of HATs and HDACs 3, 4 . In addition to modifying gene transcription via histone acetylation, HATs/HDACs also target non-histone proteins affecting their stability, localization and function 5, 6 . In mammals eighteen HDACs have been identified, which can be divided into four classes based on structure and cellular localization 4 . The majority of these HDACs, i.e. class I, II and IV, depend on zinc 2+ for their activity, while only class III HDACs (referred to as sirtuins) require NAD + .
While cancer historically has been viewed as a disease originating from genetic alterations, recent findings have implicated epigenetic aberrations in the initiation and progression of human cancer 7 . For example, expression of the tumor-suppressor genes CDKN2A, APC and MLH1, is commonly silenced through promoter hypermethylation, while in hematological cancers histone modifying enzymes such as HDACs and HMTs are aberrantly localized to the genome through recruitment via For personal use only. on September 14, 2017. by guest www.bloodjournal.org From oncogenic fusion proteins 7, 8 . The recent discovery of recurrent mutations in genes encoding the DNA methylation regulators DNMT3A and TET2, the HMT EZH2 and the HATs CREBBP and EP300 in human tumors further underpin the importance of epigenetic aberrations in tumorigenesis. Unlike genetic mutations, these are potentially reversible, implicating approaches to target epigenetic writers, erasers and readers as promising and feasible strategies for cancer therapy 2,9 . Numerous HDAC inhibitors (HDACis) have been developed, the majority of which lack isoform-selectivity and broadly inhibit various zinc 2+ -dependent HDACs 10, 11 .
HDACis demonstrate single-agent clinical activity against various hematological malignancies, including different T-cell lymphomas and acute myeloid leukemia (AML) [12] [13] [14] [15] [16] [17] [18] , which has led to the FDA approval of vorinostat (targeting class I, II and IV HDACs) as well as the more selective HDACi romidepsin (class I HDAC-specific) for treatment of cutaneous T-cell lymphoma. The exact mechanism(s) responsible for the observed HDACi-mediated anti-tumor activity is still largely unclear, and may depend on tumor type and the tumor genetic background.
The AML1-ETO fusion protein produced as a result of the t(8;21) chromosomal translocation is pathogenic for AML in collaboration with secondary mutagenic hits to genes such as FLT3, c-KIT, N-RAS and K-RAS 19 . AML1-ETO recruits a vast array of transcription factors and epigenetic regulatory proteins (e.g. C/EBPa, GATA1, E proteins, HDACs, p300, PRMT1, SON) and complexes (e.g. N-CoR, AETFC) 20-29 that putatively play important roles in the onset and/or progression of t(8;21) AML.
Several studies have proposed the therapeutic potential of HDACis in t(8;21) AML [30] [31] [32] [33] , but some controversy exists regarding the mechanism by which HDACis mediate For personal use only. on September 14, 2017. by guest www.bloodjournal.org From their effect. Treatment of A/E-positive Kasumi-1 cells with HDACis in vitro leads to tumor cell differentiation, which in some instances is accompanied by apoptosis 32, 33 .
In contrast, the single study so far that has tested HDACis in vivo for t(8;21) AML indicated that cellular differentiation was not essential for the therapeutic effect observed. That study suggested that HDACi efficacy relied on the extrinsic apoptotic pathway mediated primarily by TRAIL and its cognate receptor (DR5), which are both upregulated by HDACis in a tumor cell-selective manner 31 . A potential confounding issue with most published studies testing the applicability of HDACis in t(8;21) AML is the use of valproic acid (VPA) as the HDACi. VPA is at best a weak HDACi 34 resulting in its use at millimolar concentrations to induce histone hyperacetylation, raising concerns about potential off-target effects.
Herein we used a recently developed tractable mouse model of t(8;21) AML 35 that is to identify the molecular and biological events that underpin the therapeutic effects of HDACi. We focused on panobinostat, which has strong inhibitory activity at low nanomolar concentrations against class I, II and IV HDACs 34, 36 . In this transplantable model, AML develops as a result of the coexpression of AML1/ETO9a (A/E9a) 37 and oncogenic Nras (Nras G12D ). In A/E9a;Nras G12D -driven leukemia HDAC inhibition triggered proteasomal degradation of AE/9a leading to terminal differentiation, subsequent decrease in tumor burden and therapeutic efficacy. To our knowledge, this is the first definitive evidence that HDACi-mediated differentiation of t(8;21) AML cells results in a clear therapeutic benefit. Moreover, we have identified the biological and molecular processes that underpin the therapeutic effects of HDACis in this setting. 
Fetal liver cell isolation, retroviral transduction and transplantation
E13.5-15 fetal liver cells were cultured in the presence of IL-3, IL-6 and SCF. For production of retrovirus-containing supernatant, Phoenix packaging cells were transfected with MSCV-AML1/ETO9a-IRES-GFP (A/E9a), MSCV-luciferase-IRES-Nras G12D , MSCV-MLL-AF9-IRES-VENUS (M/A), MSCV-MLL-ENL-IRES-GFP (M/E), MSCV-Bcl-2-IRES-mCherry, TREtight-dsRed-IRES-AML1/ETO9a or MSCV-Nras G12D -IRES-tTA expression constructs. Supernatants were mixed in a 1:1 ratio and used to transduce fetal liver cells in RetroNectin (TaKaRa Bio)-precoated 6well plates. Two days after the last viral hit, 1x10 6 total cells per recipient were injected i.v. into lethally irradiated C57BL/6 mice.
Monitoring leukemia
Whole-body bioluminescent imaging (BLI) was assessed with an IVIS100 imaging system (Caliper LifeSciences). Mice were injected intraperitoneally with 50mg/kg D-Luciferin (Caliper LifeSciences), anesthetized with isoflurane, and imaged for 2min
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From after a 15min incubation following injection. Blood (~30µl) was obtained from the retro-orbital sinus. White cell counts were measured using an Advia 120 automated hematology analyzer (Bayer Diagnostics) and percentage of GFP-positive or dsRedpositive cells were analyzed by flow cytometry. At terminal disease stage, mice were sacrificed and leukemia cells were isolated from bone marrow (femur) and spleen.
Single cell suspensions were prepared and cells were cryopreserved in FCS/10% DMSO.
In vivo experiments
Leukemia cells (1x10 6 ) were transplanted into non-irradiated (M/E;Nras G12D and M/A;Nras G12D leukemias) or sub-lethally irradiated mice (A/E9a;Nras G12D leukemias) by i.v. injection. Treatment was initiated once leukemia was clearly established as demonstrated by visible bioluminescence and/or when there were 5-20% GFPpositive cells in peripheral blood. Mice were treated daily with panobinostat (25mg/kg, five consecutive days per week i.p. injection for one week followed by 15mg/kg for three to four weeks) or vorinostat (200mg/kg, seven consecutive days per week i.p. for one week followed by 150mg/kg for three to four weeks). This dosing schedule of panobinostat was well tolerated by recipient mice (Supplementary Fig   1A) . Control mice received the equivalent volume of vehicle. Mortality events from advancing leukemia were recorded for the analysis of therapeutic efficacy.
For short-term drug response studies, mice received 25mg/kg panobinostat, 100mg/kg cytarabine or equivalent volume of vehicle by i.p. injection once daily for indicated period prior to harvesting of spleen and bone marrow.
For inducible knockdown studies, mice received 2mg/ml doxycycline via drinking water (2% saccharose) and food two weeks after reconstitution of mice with transduced Nzeg-eGFP fetal liver cells. 
Flow cytometry
Cell suspensions were incubated in red cell lysis buffer (150mM NH 4 Cl, 10mM KHCO 3 , 0.1mM EDTA) and washed twice in FACS staining buffer (PBS supplemented with 1% FCS and 0.02% NaN 3 ). Cells were pre-incubated with anti-CD16/CD32 (2.4G2) and stained on ice with antibodies specific for c-Kit (CD117) and Mac-1 (CD11b) (both BD Biosciences) in FACS staining buffer for 30min. Data were collected on a FACSCanto II flowcytometer (BD Biosciences) and analyzed using FlowJo software (Tree Star).
Cell Culture

Kasumi cells were cultured in RPMI-1640 + 10% Fetal calf serum (FCS) while A/E9a
were cultured in a high-glucose version of DMEM supplemented with 10% FCS, Primary human t(8;21) cells were cultured at a starting density of 7.5 × 105 cells/ml in serum-free media consisting of IMDM supplemented with 20% BIT (Stem Cell Technologies), 100ng/ml SCF, 100ng/ml FLT3 ligand, 100ng/ml TPO and 20ng/ml IL-6 (all Peprotech) and stimulated with panobinostat for 6 or 24h at the indicated concentration. For immunoprecipitations, cell lysates were precleared by incubation with protein A or G sepharose beads (GE Healthcare) for 30min, washed in lysis buffer, incubated with anti-AML-1 or anti-Hsp90 antibodies for 30min and then crosslinked to protein A or G sepharose beads at 4°C overnight. Beads were washed 5 times with lysis buffer before addition of 5x denaturing loading buffer, heating at 95°C and analysis by SDS-PAGE.
Western Blot analysis and Immunoprecipitation
Quantitative RT-PCR
RNA was isolated using commercially available kit (Qiagen). Synthesis of cDNA was performed following standard protocols using MMLV Reverse Transcriptase (Promega). Quantitative RT-PCR was performed using SYBR Green (Applied Biosystems) method in a 384-well format using the ABI Prism7900HT (Applied Biosystems). For quantification, the C T values were obtained and normalized to the C T values of HPRT gene. Fold changes in expression were calculated by the 2 -DDCT method.
Histology
Mice femora were fixed in 10% neutral buffered formalin before decalcification using formic acid and embedding in paraffin. TUNEL staining was performed using the Apoptag Peroxidase In Situ Apoptosis Detection Kit (Chemicon) kit. Sections were counterstained using hematoxylin and images were recorded with a Zeiss microscope and a 20x lens. For cytospins, bone marrow cells were stained with Romanowski stain solution.
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Statistical analysis
Kaplan-Meier survival curves were created and survival of mice (using a log-rank test) was statistically analyzed with GraphPad Prism software (GraphPad software).
All other statistical analyses (using a two-tailed unpaired t test) were also performed with this software.
RESULTS
A/E9a;Nras G12D -driven leukemia is susceptible to the HDACi panobinostat
Recipient mice transplanted with fetal liver cells transduced with retroviral vectors encoding A/E9a (coexpressing GFP), and Nras G12D (coexpressing firefly luciferase) developed AML. Leukemic cells expressed A/E9a ( Figure 1A) , were GFP-positive ( Figure 1B ) and expressed c-Kit (CD117), but not Mac-1 (CD11b) or other lineage markers ( Figure 1B and data not shown). Consistent with the previously identified interaction between A/E and HDACs 20,21,38-40 , immunoprecipitation assays confirmed the interaction between HDAC1 and A/E9a in primary A/E9a;Nras G12D leukemic cells ( Figure 1C ). Similar experiments were performed to determine if HDAC2 and -3 also associated with A/E9a, and while HDAC2 immunoprecipitated with A/E9a, no physical interaction was detected between HDAC3 and A/E9a (data not shown).
Treatment with panobinostat had no acute effect on the interaction of HDACs with
A/E9a ( Figure 1C and data not shown). A/E9a;Nras G12D tumors harvested from tumor-bearing mice treated with panobinostat for 4 cycles were assessed by flow cytometry for GFP expression and expression for c-Kit and Mac-1. As shown in supplemental figure 1E, cells chronically exposed to panobinostat retained their immature AML phenotype. Moreover, mice transplanted with GFP-positive A/E9a;Nras G12D tumors harvested from mice that had received eight cycles of panobinostat treatment and subsequently treated with panobinostat showed a robust therapeutic response (Supplemental Figure 1F ), similar to mice bearing A/E9a;Nras G12D tumors not previously exposed to panobinostat.
To determine whether panobinostat was also effective in other AML subtypes, we 
Response to panobinostat is independent of a functional p53 pathway
Standard treatment for AML patients currently consists of cytarabine in combination
with an anthracycline such as doxorubicin 41 . Many standard chemotherapeutics rely on an intact p53 pathway for an optimal therapeutic response 42 and we have shown that p53-deficient A/E9a;Nras G12D leukemias were refractory to standard chemotherapy 35 (Supplemental Figure 3A ). We previously showed that the apoptotic 1 4 and therapeutic effects of HDACis in a B-cell lymphoma model occurred in the absence of wild type p53 43,44 , and we wished to investigate the response of p53deficient A/E9a;Nras G12D leukemias to panobinostat. Panobinostat reduced the leukemic burden and significantly prolonged the survival of mice bearing highly aggressive A/E9a; Figure 3B ).
These results suggest that HDACis may provide a therapeutic option in p53-deficient AML that is commonly resistant to conventional induction therapy 45 . Overexpression of Bcl-2 (Supplemental Figure 4A ) also had no effect on the sensitivity of A/E9a;Nras G12D leukemias to panobinostat in vivo ( Figures 4A-B ). Mice bearing these leukemias treated with panobinostat clearly had a survival benefit over 1 5 vehicle-treated mice ( Figure 4C and Supplemental Figure 4B ). These data imply that tumor cell apoptosis was not the primary biological response of A/E9a;Nras G12D leukemias to panobinostat. Consistent with this observation, little or no TUNELpositive tumor cells were detected in leukemia-bearing mice following treatment with panobinostat ( Figure 4D and Supplemental Figure 7 ). In contrast, treatment with cytarabine led to a substantial increase in TUNEL-positive tumor cells ( Figure 4D and Supplemental Figure 7 ). Despite their failure to undergo apoptosis in response to panobinostat, A/E9a;Nras G12D leukemias were reduced in spleen, bone marrow and peripheral blood within 3-7d post treatment ( Figure 4E ). Hence, while A/E9a;Nras G12D leukemias can undergo apoptosis in response to certain anti-cancer agents, our data strongly implicate a non-apoptotic primary effector mechanism for panobinostat.
Induction of apoptosis is dispensable for a therapeutic response to panobinostat
Panobinostat induces differentiation of A/E9a;Nras G12D AML.
Treatment of primary A/E9a;Nras G12D leukemias with panobinostat in vitro resulted in a reduction in the number of cells in S-phase ( Figure 5A ) and biochemical changes characteristic with a block in cell cycle at the G1/S checkpoint including increased expression of p21 WAF1/CIP1 and p16 INK4A , and hypophosphorylation of pRb ( Figure   5B ). These changes in cell proliferation were concomitant with a decrease in expression of c-Kit following treatment with panobinostat for 24 or 48h ( Figure 5C ).
No change in c-Kit expression was seen following treatment of A/E9a;Nras G12D cells with etoposide ( Figure 5C ) demonstrating the specific effect of panobinostat.
Concomitant with panobinostat-mediated induction of tumor cell cycle arrest and decreased expression of c-Kit an increase in mRNA for the pro-myeloid 1 6 differentiation transcription factors PU-1, GATA-2, SCL and C/EBP alpha was observed ( Figure 5D ).
To confirm that panobinostat was inducing tumor cell differentiation the effect of Mac-1 ( Figure 5G ). Histological analysis revealed that A/E9a;Nras G12D leukemic cells from panobinostat-treated leukemic mice displaying a more granulocyte/macrophagelike appearance ( Figure 5H ).
Panobinostat mediates proteasome-dependent degradation of A/E9a.
It has previously been observed that treatment of human Kasumi-1 cells with the class I-selective HDACi romidepsin resulted in apoptosis and reduced expression of A/E 33 .
Treatment of A/E9a;Nras G12D leukemic blasts with panobinostat in vitro for as little as 6h caused a marked decrease in expression of A/E9a concomitant with histone H3 hyperacetylation ( Figure 6A ). Importantly, there was no change in expression of GFP, which in our experimental system is coexpressed with A/E9a ( Figure 6A ), and there was no substantial change in the levels of A/E9a mRNA over a 24h time-course (data not shown). We next treated Kasumi-1 cells with panobinostat and demonstrated a similar decrease in A/E with kinetics similar to those observed using the mouse A/E9a;Nras G12D leukemias ( Figure 6B ). In addition, primary human t(8;21) AML 1 7 cells treated with panobinostat also showed time-dependent decrease in A/E ( Figure   6C , D). These data demonstrate that panobinostat induces degradation of full length A/E and the A/E9a fusion protein with similar kinetics. Co-treatment of A/E9a;Nras G12D leukemic cells with panobinostat and the proteasome inhibitor MG-132 partially rescued the panobinostat-mediated decrease in A/E9a ( Figure 6E ), suggesting that panobinostat triggered proteasome-mediated decay of A/E9a. A/E has previously been shown to be a client protein for the molecular chaperone Hsp90 33 , suggesting that HDACi-mediated hyperacetylation of Hsp90 may be sufficient to mediate degradation of A/E9a. Treatment of A/E9a;Nras G12D leukemic blasts in vitro with the Hsp90 inhibitor 17-AAG resulted in a rapid loss in expression of A/E9a
( Figure 6F ), supporting previous studies demonstrating that that A/E is a client protein of Hsp90 33 and that disruption in the association of A/E9a with Hsp90 may trigger its degradation. Immunoprecipitation assays showed that A/E9a physically interacted with Hsp90, which was diminished upon treatment with panobinostat ( Figure 6G ) and marginally reduced following treatment with 17-AAG (Supplemental Figure 9 ).
Taken together, these data demonstrate that A/E9a is an Hsp90 client protein and treatment with panobinostat promotes dissociation of A/E9a from Hsp90 and supports a model in which hyperacetylation of Hsp90 results in subsequent ubiquitination and proteasomal degradation of A/E9a.
Inducible deletion of A/E9a phenocopies the effect of panobinostat.
To determine if genetic deletion of A/E9a phenocopied the effects of panobinostat we suggests that the Tet-off system used to express A/E9a in a regulated manner is not 100% effective in a small proportion of cells and these cells eventually grow out to kill the mouse.
As seen following in vivo treatment of mice bearing A/E9a;Nras G12D leukemias with panobinostat, genetic depletion of A/E9a was accompanied by a decrease in c-Kitpositive cells ( Figure 7C ), an increase in Mac-1-positive cells ( Figure 7D ), and an increase in genes (M/CSF receptor, CEBPalpha and PU.1) associated with myeloid differentiation ( Figure 7E ). Moreover, histological analysis revealed that A/E9a;Nras G12D leukemic cells harvested from doxycycline-treated leukemic mice assumed a differentiated granulocyte/macrophage-like morphology similar to that observed following treatment with panobinostat (Supplementary Figure 10D) .These data demonstrate that a reduction in the expression of A/E9a in primary leukemias phenocopies the molecular, biological and therapeutic effects of panobinostat treatment. panobinostat as monotherapy results in a therapeutic response that is associated with myeloid differentiation and degradation of A/E9a. We noted that upon cessation of panobinostat treatment, mice relapsed with disease that was pathologically and phenotypically similar to the original disease. We posit that using the regime undertaken in this study, panobinostat was unable to induce differentiation of all A/E9a;Nras G12D tumors and mice therefore subsequently relapsed. This is supported by our studies demonstrating that panobinostat remained fully effective in mice transplanted with A/E9a;Nras G12D cells harvested from mice previously treated with panobinostat (Supplemental figure 1E) . Moreover, FACS analysis of A/E9a;Nras G12D cells harvested from mice treated with vehicle or panobinostat for 4 weeks revealed no change in hemopoietic cell surface markers (Supplemental figure 1D ). Finally, we have performed studies showing transplantation of only one A/E9a;Nras G12D tumor into recipient mice was sufficient to induce fatal disease in recipient mice. Previous studies proposed that tumor-specific induction of the TRAIL death receptor pathway was responsible for the anti-tumor effects of HDACis 31,46 . Consistent with those studies, we found that Dr5 was transcriptionally activated following treatment of A/E9a;Nras G12D leukemias with panobinostat. However, A/E9a;Nras G12D leukemias with genetic knockout of either Dr5 or Trail were equally sensitive to panobinostat treatment as unmodified A/E9a;Nras G12D leukemias providing definitive genetic evidence that the TRAIL signaling pathway plays no role in mediating the anti-tumor response to HDACis in A/E9a-driven leukemia. In contrast to our previous studies using the Eμ-myc model of B cell lymphoma, which demonstrated a direct link between activation of the intrinsic apoptosis pathway and therapeutic efficacy 43,44 , we saw no evidence of apoptosis following treatment of A/E9a tumors with panobinostat.
These findings indicate that the molecular and biological effector mechanisms of HDACis identified for one tumor type may not be directly translatable to another and highlight the importance of testing anti-cancer drugs in physiologically relevant and genetically tractable pre-clinical models of disease. Panobinostat treatment also provided a significant survival benefit to mice bearing A/E9a;Nras G12D /p53 -/leukemias however the survival benefit was less pronounced than that observed using A/E9a;Nras G12D with wild type p53. We and others have demonstrated that a functional p53 is not required for HDACis to induce tumor cell apoptosis (see ref 10
and references therein). However, it is possible that p53 is required for HDACis to induce a robust differentiation response as has been recently demonstrated for the treatment of MLL-ENL/Hras V12D -driven AML treated with DNA damaging agents 54 .
Although A/E has been shown to be a direct target of HATs and in fact the Meier survival curves of treated M/E;Nras G12D leukemia recipient mice following initiation of therapy (n=6 for vehicle, n=6 for panobinostat; median survival benefit 6d, p=0.0015). A/E9a;Nras G12D /DR5 -/leukemia recipient mice following initiation of therapy (n=10 for vehicle, n=10 for panobinostat; median survival benefit 45d, p<0.0001). For personal use only. on September 14, 2017. by guest www.bloodjournal.org From 
Dotted line represents final day of treatment.
